Real-time bioenergetic profiles also showed that IGU treated CD4+ T cells have lower glycolysis and glycolytic capacity, which implied IGU also played a key role in regulating the T cells in other diseases which are characterized by glycolysis, such as systemic lupus erythematosus (SLE). Here, CD4 is linked to systemic lupus erythematosus.